PJ NICHOLOFF STEROID PROTOCOL
Individuals with Duchenne Muscular Dystrophy (DMD) who take glucocorticoids (including prednisone, prednisolone, deflazacort, and vamorolone) are at risk of adrenal suppression. This means their bodies cannot produce cortisol normally during times of stress. All patients on steroids need a stress steroid plan for illness, injury, or surgery and must follow a careful tapering schedule when reducing or stopping steroids to prevent potentially life-threatening complications.
PJ NICHOLOFF STEROID PROTOCOL applies to individuals with muscular dystrophy who are treated with glucocorticoids (GCs), including Duchenne muscular dystrophy (DMD), Becker muscular dystrophy, female manifesting carriers, and X-linked cardiomyopathy (collectively abbreviated as DBMD).
Vamorolone (AGAMREE®) Information Sheet for Healthcare Providers
Vamorolone (AGAMREE®), is a new steroid used to treat Duchenne muscular dystrophy (DMD). It is designed to offer the same muscle-strengthening benefits as classic steroids—such as prednisone, prednisolone, and deflazacort—while potentially reducing some of the common side effects associated with these medications.
This information sheet has been prepared by OPTIMIZE DMD to provide necessary information for Healthcare Providers to help individuals living with DMD and their families better understand the role of Vamorolone in DMD treatment.